Happe Spine expects to receive FDA clearance within the next two to three months for its new porous, bioactive material that encourages bone growth, according to the report.
After FDA review, Happe plans to target hospitals, ASCs and orthopedic practices.
Last year, Happe closed on a $3.35 million series A funding round, and an additional $2 million round this year.
